Dominari Holdings Posts $1.1M Loss Amid Strategic Shift

TL;DR

DOMH is still bleeding cash with a $1.1M loss, and its constant identity changes scream 'avoid' for any serious investor.

AI Summary

Dominari Holdings Inc. reported a net loss of $1.1 million for the three months ended June 30, 2025, a significant increase from the $0.5 million net loss in the prior-year period. Revenue for the quarter was not explicitly detailed as a primary focus, indicating a continued pre-revenue or early-stage operational phase for its core business. The company, formerly Aikido Pharma Inc., continues to operate as a non-accelerated filer and a smaller reporting company, reflecting its market capitalization and operational scale. Key business changes include its ongoing transformation from a pharmaceutical focus to a diversified holding company, as evidenced by its name change from Aikido Pharma Inc. in 2021. Risks include its history of name changes (from SPHERIX INC in 2001 to Aikido Pharma Inc. in 2020, then Dominari Holdings Inc. in 2021), which can signal strategic shifts or struggles, and its consistent net losses. The strategic outlook involves leveraging its holding company structure, though specific growth initiatives or revenue-generating segments were not detailed in this filing. The company's common stock is listed on The Nasdaq Capital Market under the symbol DOMH.

Why It Matters

Dominari Holdings' continued net losses, reaching $1.1 million this quarter, signal ongoing challenges for investors seeking profitability. The company's history of multiple name changes, from SPHERIX INC to Aikido Pharma Inc. and now Dominari Holdings Inc., suggests a lack of stable strategic direction, which could erode investor confidence and make it difficult for employees to align with a clear vision. For customers, the impact is less direct given the holding company structure, but a struggling parent could affect subsidiary operations. In a competitive market, companies with consistent losses and shifting identities often struggle to attract capital and talent, putting Dominari at a disadvantage against more focused and profitable peers.

Risk Assessment

Risk Level: high — The risk level is high due to the reported net loss of $1.1 million for the three months ended June 30, 2025, indicating continued unprofitability. Furthermore, the company's history of multiple name changes (SPHERIX INC, Aikido Pharma Inc., Dominari Holdings Inc.) over two decades suggests a lack of consistent business strategy and potential operational instability, which are significant red flags for investors.

Analyst Insight

Investors should exercise extreme caution and consider avoiding DOMH given its consistent net losses and history of strategic pivots. Await clear evidence of sustained revenue generation and a defined, profitable business model before considering any investment.

Key Numbers

• $1.1M — Net Loss (Increased from $0.5M in the prior-year period, indicating worsening financial performance.)
• 2025-06-30 — Quarter End Date (The period for which the financial results are reported.)
• 001-41845 — Commission File Number (Unique identifier for SEC filings, indicating the company's registration status.)
• 52-0849320 — I.R.S. Employer Identification No. (Federal tax identification number for the company.)
• 2021-01-11 — Date of Name Change (When Aikido Pharma Inc. became Dominari Holdings Inc., highlighting a strategic pivot.)

Key Players & Entities

• Dominari Holdings Inc. (company) — registrant of the 10-Q filing
• Aikido Pharma Inc. (company) — former name of Dominari Holdings Inc. until 2021
• SPHERIX INC (company) — former name of Aikido Pharma Inc. until 2001
• The Nasdaq Capital Market (regulator) — exchange where DOMH common stock is registered
• United States Securities and Exchange Commission (regulator) — governing body for SEC filings
• $1.1 million (dollar_amount) — net loss for the three months ended June 30, 2025
• $0.5 million (dollar_amount) — net loss for the three months ended June 30, 2024
• June 30, 2025 (date) — end of the quarterly reporting period
• Delaware (location) — state of incorporation for Dominari Holdings Inc.
• New York (location) — business address city for Dominari Holdings Inc.

FAQ

Risk Factors

• History of Name Changes [medium — operational]: The company has undergone multiple name changes, from SPHERIX INC in 2001 to Aikido Pharma Inc. in 2020, and then to Dominari Holdings Inc. in 2021. This pattern can indicate significant strategic shifts, potential past struggles, or a lack of stable long-term direction, which may concern investors.
• Consistent Net Losses [high — financial]: Dominari Holdings Inc. reported a net loss of $1.1 million for the three months ended June 30, 2025, an increase from the $0.5 million net loss in the prior-year period. This trend of consistent net losses, without clear revenue generation from its core business, suggests ongoing financial challenges and a need for successful future monetization strategies.
• Pre-Revenue or Early-Stage Operations [high — market]: The company's financial reporting does not explicitly detail revenue as a primary focus, suggesting it is in a pre-revenue or early-stage operational phase. This lack of current revenue generation means the company is reliant on future business development and investment to achieve profitability.

Industry Context

Dominari Holdings Inc. operates within the financial services sector, specifically as a security broker, dealer, and flotation company (SIC code 6211). This industry is characterized by high competition, regulatory oversight, and sensitivity to market conditions. As a holding company, Dominari's strategy likely involves acquiring or managing stakes in various businesses, potentially across different sectors, rather than focusing on a single operational area.

Regulatory Implications

As a non-accelerated filer and smaller reporting company, Dominari Holdings Inc. is subject to less stringent SEC reporting requirements. However, its history of name changes and consistent net losses could attract scrutiny from regulators and investors regarding its business stability and transparency.

What Investors Should Do

1. Monitor for specific revenue-generating initiatives.
2. Analyze the diversification strategy.
3. Evaluate the trend of increasing net losses.

Key Dates

• 2025-06-30: Quarter End Date — Marks the end of the reporting period for the current 10-Q filing, providing the latest financial snapshot.
• 2021-01-11: Name Change to Dominari Holdings Inc. — Signifies a major strategic pivot from its previous identity as Aikido Pharma Inc., indicating a shift in business focus.
• 2020-03-17: Name Change to Aikido Pharma Inc. — Represents a prior strategic shift, highlighting a history of evolving business direction.
• 2001-08-15: Name Change from SPHERIX INC — Indicates the earliest known name change, further underscoring a long-standing pattern of corporate identity evolution.

Glossary

Non-accelerated filer

A company that does not meet the criteria for accelerated filer status, typically due to lower market capitalization or public float. (Indicates Dominari Holdings Inc. is a smaller company with less stringent SEC filing requirements compared to larger corporations.)

Smaller reporting company

A company that meets certain criteria related to public float and annual revenue, allowing for scaled disclosure requirements. (Reinforces Dominari Holdings Inc.'s relatively small size and the simplified reporting obligations it is subject to.)

Holding company

A company whose primary business is holding a controlling interest in the securities of other companies, rather than engaging in direct business operations. (Explains Dominari Holdings Inc.'s current strategic structure, suggesting it aims to manage a portfolio of diverse businesses.)

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a continuing view of a company's financial position during the year. (This document is the source of the financial information and analysis presented, detailing the company's performance for the specified quarter.)

Year-Over-Year Comparison

The most recent 10-Q filing for Dominari Holdings Inc. shows a worsening financial performance, with a net loss of $1.1 million for the quarter ended June 30, 2025, compared to a $0.5 million net loss in the prior-year period. Revenue details were not a primary focus, indicating the company remains in an early-stage or pre-revenue phase. No new significant risks were detailed, but the existing concerns around its history of name changes and consistent losses remain relevant.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock ($0.0001 par value per share) DOMH The Nasdaq Ca

Filing Documents

• ea0252311-10q_dominari.htm (10-Q) — 875KB
• ea025231101ex31-1_dominari.htm (EX-31.1) — 10KB
• ea025231101ex31-2_dominari.htm (EX-31.2) — 10KB
• ea025231101ex32-1_dominari.htm (EX-32.1) — 5KB
• ea025231101ex32-2_dominari.htm (EX-32.2) — 5KB
• 0001213900-25-074425.txt ( ) — 5905KB
• domh-20250630.xsd (EX-101.SCH) — 53KB
• domh-20250630_cal.xml (EX-101.CAL) — 43KB
• domh-20250630_def.xml (EX-101.DEF) — 259KB
• domh-20250630_lab.xml (EX-101.LAB) — 493KB
• domh-20250630_pre.xml (EX-101.PRE) — 284KB
• ea0252311-10q_dominari_htm.xml (XML) — 815KB

- Financial Information

Part I - Financial Information Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations for the Three and Six months ended June 30, 2025 and 2024 (Unaudited) 2 Condensed Consolidated 3 Condensed Consolidated Statements of Cash Flows for the Six months ended June 30, 2025 and 2024 (Unaudited) 5 Notes to the Condensed Consolidated Financial Statements (Unaudited) 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

- Other Information

Part II - Other Information Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3. Defaults Upon Senior Securities 30 Item 4. Mine Safety Disclosures 30 Item 5. Other Information 30 Item 6. Exhibits 31

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements DOMINARI HOLDINGS INC. Condensed Consolidated Balance Sheets ($ in thousands except share and per share amounts) June 30, 2025 December 31, 2024 ASSETS (Unaudited) Current assets Cash and cash equivalents $ 9,469 $ 4,079 Marketable securities 18,772 5,773 Receivable from clearing brokers 30,986 17,279 Prepaid expenses and other assets 1,124 1,019 Total current assets 60,351 28,150 Property and equipment, net 187 239 Notes receivable, at fair value - non-current portion - 902 Long term equity investments 43,744 12,282 Loans to employees 1,865 2,150 Right-of-use assets 2,733 2,944 Security deposit 458 458 Total assets $ 109,338 $ 47,125 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable and accrued expenses $ 2,610 $ 919 Accrued commissions 13,005 2,057 Lease liability - current 418 410 Contract liabilities – current 436 240 Other current liabilities 65 157 Total current liabilities 16,534 3,783 Lease liability, less current portion 2,442 2,629 Contract liabilities, less current portion 1,762 860 Total liabilities 20,738 7,272 Stockholders' equity Preferred stock, $ 0.0001 par value, 50,000,000 authorized Convertible Preferred Series D: 5,000,000 shares designated 3,825 shares issued and outstanding as of June 30, 2025 and December 31, 2024 liquidation value of $ 0.0001 per share - - Convertible Preferred Series D-1: 5,000,000 shares designated 834 shares issued and outstanding as of June 30, 2025 and December 31, 2024 liquidation value of $ 0.0001 per share - - Common stock, $ 0.0001 par value, 100,000,000 shares authorized 15,295,930 and 7,037,022 shares issued as of June 30, 2025 and December 31, 2024, respectively 15,235,782 and 6,976,874 shares outstanding as of June 30, 2025 and December 31, 2024 - - Additional paid-in capital 334,475 263,820 Treasury stock, as of cost, 60,148 shares as o

Financial Statements

Financial Statements (Unaudited) Note 1. Organization and Description of Business and Recent Developments Organization and Description of Business Dominari Holdings Inc. (the "Company"), formerly Aikido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Dominari Labs, LLC (formerly Aikido Labs, LLC). In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. ("Dominari Financial"), with the intent of shifting the Company's primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC ("Dominari Securities"), an introducing broker- dealer, a member of the Financial Industry Regulatory Authority ("FINRA") and an investment adviser registered with the Securities and Exchange Commission ("SEC"). Dominari Securities is also licensed to provide investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the "FPS Purchase Agreement") with Fieldpoint Private Bank & Trust ("Seller"), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company ("FPS"), that is a broker-dealer, a member of FINRA and an investment adviser registered with the SEC. Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100 % of the membership interest

View Full Filing

View this 10-Q filing on SEC EDGAR